Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study

NCT06172699 · View on ClinicalTrials.gov ↗

Study Summary

This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable Cardiac Monitor (ICM) device.

Interventions

  • DEVICE Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device

Study Locations (11)

Texas

  • Shannon Clinic — San Angelo
  • Methodist Texsan Hospital — San Antonio
  • Heart Rhythm Associates — The Woodlands

California

  • University of California at San Diego (UCSD) Medical Center — San Diego

Florida

  • Orlando Health — Orlando

Kansas

  • Kansas City Cardiac Arrhythmia Research Foundation — Overland Park

Michigan

  • Trinity Health-Michigan d/b/a Michigan Heart — Ann Arbor

New York

  • St. Peter's Health Partners Medical Associates, PC — Albany

South Carolina

  • Trident Medical Center — Charleston

Tennessee

  • Erlanger Medical Center — Chattanooga

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-01-01
Est. Completion 2025-12-24

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06172699

The ClinicalTrials.gov registry entry for NCT06172699 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Cardiac Arrhythmia appearing as the primary indexed condition, and to 1 intervention — of which Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06172699 reports 11 study locations spanning 9 distinct geographic areas — top geographies include Texas, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06172699 about?

NCT06172699 is a clinical study titled "Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study". This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable Cardiac Monitor (ICM) device.

What is the current status of trial NCT06172699?

This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2024-01-01. Estimated completion is 2025-12-24.

What conditions does trial NCT06172699 study?

This clinical trial studies the following conditions: Cardiac Arrhythmia, Ablation, Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06172699?

The interventions under investigation include: Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06172699?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06172699 being conducted?

This trial has 11 study locations across California, Florida, Kansas, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial